DOI:
10.1055/s-00000041
Neuropediatrics
LinksClose Window
References
Haas M, Vlcek V, Balabanov P. , et al.
European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.
Neuromuscul Disord 2015;
25 (01) 5-13
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.